Certain bis(heteroaryl)piperazines (BHAPs) are potent inhibitors of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) at concentrations lower by 2-4 orders of magnitude than that which inhibits normal cellular DNA polymerase activity. Combination of a BHAP with nucleoside analog IIV-1 RT inhibitors suggested that together these compounds inhibited RT synergistically. In three human lymphocytic cell systems using several laboratory and clinical HIV-1 isolates, the BHAPs blocked HIV-1 replication with potencies nearly identical to those of 3'-azido-2',3'-dideoxythymidine or 2',3'-dideoxyadenosine; in primary cultures of human peripheral blood mononuclear cells, concentrations of these antiviral agents were lower by at least 34 orders of magnitude than cytotoxic levels. The BHAPs do not inhibit replication of HIV-2, the simian or feline immunodeficiency virus, or Rauscher murine leukemia virus in culture. Evaluation of a BHAP in HIV-1-infected SCID-hu mice (severe combined ict mice implanted with human fetal lymph node) showed that the compound could block HIV-1 replication in vivo. The BHAPs are readily obtained synthetically and have been extensively characterized in preclinical evaluations. These compounds hold promise for the treatment of HIV-1 infection.The reverse transcriptase (RT) encoded by human immunodeficiency virus type 1 (HIV-1) catalyzes the conversion of the viral genomic RNA into proviral DNA (1, 2). Since RT is essential for virus replication and has no closely related identified cellular homolog, it has been the prime target for antiviral therapy against theacquired immunodeficiency syndrome (AIDS; refs. 3 and 4). This strategy is appropriate since 3'-azido-2',3'-dideoxythymidine (AZT), a nucleoside analog inhibitor of reverse transcription, was the first drug shown to benefit HIV-1-infected individuals (5). Other nucleoside analog RT inhibitors also show promise in clinical evaluations (6, 7). However, the administration of these drugs to patients is usually limited by serious toxicities (7,8). In addition, HIV-1 with reduced AZT-sensitivity has been obtained from AZT-treated patients, suggesting the emergence of resistant virus will limit the drug's efficacy (9, 10). Thus, effective prolonged treatment of HIV-1 infection likely requires the discovery of other, perhaps multiple, RT inhibitors. To this end, we and others (11, 12) have sought to identify other nonnucleoside HIV-1 RT inhibitors. MATERIALS AND METHODSCell Culture and Virus Infections. The cell cultures were maintained at 370C in 5% C02/95% air. The HIV-1 infectivity studies were conducted in MT-2 cells, peripheral blood mononuclear cells (PBMC), and H9 cells as described (9,(13)(14)(15). In brief, MT-2 or H9 cells were infected with HIV-1 (IlIb isolate) at a multiplicity of infection of 0.001. In MT-2 cells syncytium formation was determined 4 days after infection at the peak of the viral cytopathic effect (13). In H9 cells, growth medium with fresh drug was replaced every 3-4 days, and at 14 days-...
TR-701 is the orally active prodrug of TR-700, a novel oxazolidinone that demonstrates four-to eightfoldgreater activity than linezolid (LZD) against Staphylococcus and Enterococcus spp. In this study evaluating the in vitro sensitivity of LZD-resistant isolates, TR-700 demonstrated 8-to 16-fold-greater potency than LZD against all strains tested, including methicillin-resistant Staphylococcus aureus (MRSA), strains of MRSA carrying the mobile cfr methyltransferase gene, and vancomycin-resistant enterococci. The MIC 90 for TR-700 against LZD-resistant S. aureus was 2 g/ml, demonstrating the utility of TR-700 against LZD-resistant strains. A model of TR-700 binding to 23S rRNA suggests that the increased potency of TR-700 is due to additional target site interactions and that TR-700 binding is less reliant on target residues associated with resistance to LZD.Oxazolidinone antibiotics are one of the newest classes of antibiotics developed within the past 30 years, with linezolid (LZD) representing the only marketed member of this class. In 2000, LZD (Zyvox) was granted approval for the treatment of infections associated with vancomycin-resistant Enterococcus faecium, nosocomial pneumonia, community-acquired pneumonia due to Streptococcus pneumoniae and methicillin-sensitive Staphylococcus aureus (MSSA), and complicated skin and skin structure infections, including cases due to methicillinresistant Staphylococcus aureus (MRSA) (1). Later approvals included pediatric use, pneumonia due to multidrugresistant S. pneumoniae, and treatment of diabetic foot infections, without osteomyelitis, caused by gram-positive bacteria. These approvals represent important milestones for the novel oxazolidinone class in the treatment of serious infections.Oxazolidinones have been shown to bind to the 50S ribosomal subunit and inhibit protein translation (31). A model of the binding of LZD to the 23S rRNA peptidyl transferase region has been previously published, based upon in vivo crosslinking experiments (18). This model predicts that LZD would specifically interfere with the binding of the amino acid portion of the aminoacyl tRNA to the ribosomal A site. The recent crystal structure of LZD bound to the 50S ribosomal subunit confirms these findings and suggests that the mechanism of inhibition involves competition with the incoming A site substrates (13). Mutations in the 23S rRNA central loop of domain V, the peptidyl transferase center (PTC), are associated with the development of LZD resistance.
A method for examining the viscera of rat and rabbit fetuses is described. Techniques used in detecting visceral alterations in rats and rabbits for routine teratogenicity screens have varied over the years. The method used should be quick and simple but at the same time must be accurate, reliable, and comprehensive. The procedure used in this lab is a complete and systematic necropsy of the fresh fetus requiring minimum equipment and time. The examination can be done immediately following cesarean section and yields an intact skeleton which can subsequently be processed for skeletal examination. The fresh specimen and the natural coloration of in situ organs makes color photography of visceral alterations clear and concise. Any lesion can be appropriately fixed for histopathic examination. This technique begins with the examination of the organs in the abdominal cavity and proceeds to the thorax. Of special interest is the procedure used to inspect the internal anatomy of the fresh fetal heart. A description of the internal examination of both rat and rabbit heads and eyes is also included.
Bisheteroarylpiperazines are potent inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). We describe a novel bisheteroarylpiperazine, U-90152 {1-(5-methanesulfonamido-IH-indol-2-yI-carbonyl)-4-[3-(1-methylethyl-amino)pyridinyllpiperazine}, which inhibited recombinant HIV-1 RT at a 50%Y inhibitory concentration (IC.) of 0.26 FLM (compared with IC50s of >440 ,uM for DNA polymerases at and B). U-90152 blocked the replication in peripheral blood lymphocytes of 25 primary HWV-i isolates, including variants that were highly resistant to 3'-azido-2',3'-dideoxythymidine (AZT) or 2',3'-dideoxyinosine, with a mean 50%o effective dose of 0.066 + 0.137 pM. U-90152 had low cellular cytotoxicity, causing less than 8% reduction in peripheral blood lymphocyte viability at 100 ,uM. In experiments assessing inhibition of the spread of HIV-MB in cell cultures, U-90152 was much more effective than AZT. When approximately 500 HIV-1l1m-infected MT-4 cells were mixed 1:1,000 with uninfected cells, 3 ,uM AZT delayed the evidence of rapid viral growth for 7 days. In contrast, 3 ,uM U-90152 totally prevented the spread of HIV-i, and death and/or dilution of the original inoculum of infected cells prevented renewed viral growth after U-90152 was removed at day 24. The combination of U-90152 and AZT, each at 0.5 ,uM, also totally prevented viral spread. Finally, although the RT amino acid substitutions K103N (lysine 103 to asparagine) and Y181C (tyrosine 181 to cysteine), which confer cross-resistance to several nonnucleoside inhibitors, also decrease the potency of U-90152, this drug retains significant activity against these mutant RTs in vitro (IC50s, approximately 8 ,uM).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.